1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,950 | 8,250 | 30.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SHANGHAI HENLIUS BIOTECH Aktie jetzt für 0€ handeln | |||||
| Do | Organon & Co.: Europäische Kommission erteilt Marktzulassung für POHERDY (Pertuzumab) von Henlius und Organon, das erste in Europa zugelassene Biosimilar zu PERJETA (Pertuzumab) | 332 | Business Wire | Shanghai Henlius Biotech, Inc. (2696.HK) und Organon (NYSE: OGN) gaben heute bekannt, dass die Europäische Kommission die Zulassung für POHERDY (Pertuzumab) 420 mg/14 ml Injektion zur intravenösen... ► Artikel lesen | |
| Do | HENLIUS HLX3901 Injection Phase 1 Clinical Study Completes First Patient Dosing in China | 1 | AASTOCKS | ||
| Do | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX3901 INJECTION (DLL3XDLL3XCD3XCD28 TETRA-SPECIFIC ... | - | HKEx | ||
| Mi | Henlius And Organon Get EU Green Light For First Pertuzumab Biosimilar | 1 | RTTNews | ||
| Mi | Organon & Co.: European Commission (EC) Approves Henlius and Organon's POHERDY (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe | 287 | Business Wire | Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY (pertuzumab) 420 mg/14 mL injection for... ► Artikel lesen | |
| Di | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - EUROPEAN COMMISSION (EC) APPROVED HLX11 (PERTUZUMAB, TRADE NAME IN THE UNITED STATES AND EUROPE: POHERDY) ... | - | HKEx | ||
| 24.04. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE PHASE 2/3 CLINICAL TRIAL OF PIMURUTAMAB HLX07 (RECOMBINANT ANTI-EGFR HUMANISED MONOCLONAL ANTIBODY INJECTION) ... | 1 | HKEx | ||
| 24.04. | HENLIUS (02696): PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 19 MAY 2026 (OR ANY ADJOURNMENT THEREOF) | - | HKEx | ||
| 24.04. | HENLIUS (02696): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 24.04. | HENLIUS (02696): (1) ANNUAL REPORT 2025 (2) BOARD REPORT 2025 (3) BOARD OF SUPERVISORS REPORT 2025 (4) FINAL ACCOUNTS REPORT 2025 (5) PROFIT DISTRIBUTION ... | 1 | HKEx | ||
| 24.04. | HENLIUS (02696): ANNUAL REPORT 2025 | 3 | HKEx | ||
| 24.04. | HENLIUS (02696): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 24.04. | HENLIUS (02696): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | 1 | HKEx | ||
| 24.04. | HENLIUS (02696): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | 1 | HKEx | ||
| 23.04. | Alligator Bioscience Comments on Henlius Presentation of HLX49 Preclinical Data at AACR 2026 | 241 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 23, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that Shanghai Henlius Biotech, Inc. has presented preclinical data for HLX49, a HER2 biparatopic... ► Artikel lesen | |
| 17.04. | HENLIUS (02696): GRANTS OF OPTIONS AND RSUS | 1 | HKEx | ||
| 14.04. | HENLIUS HLX05-N Phase I Clinical Trial Approved | 1 | AASTOCKS | ||
| 14.04. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - PHASE 1 CLINICAL TRIAL APPLICATION OF CETUXIMAB INJECTION BIOSIMILAR HLX05-N (RECOMBINANT ANTI-EGFR CHIMERIC ... | 3 | HKEx | ||
| 10.04. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST SUBJECT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF PERTUZUMAB AND TRASTUZUMAB INJECTION (SUBCUTANEOUS ... | - | HKEx | ||
| 09.04. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE SUPPLEMENTARY APPLICATIONS FOR INDICATION EXPANSION OF HANLIKANG (RITUXIMAB INJECTION) APPROVED BY NMPA | - | HKEx |
1 2 3 4 5 Weiter >>
83 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 16,115 | -24,94 % | Summit Therapeutics falls after update on Akeso-partnered lung cancer trial | ||
| ERASCA | 10,000 | -6,10 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,720 | -1,85 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer | Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated... ► Artikel lesen | |
| HEMAB THERAPEUTICS | 34,130 | 0,00 % | Hemab Therapeutics, Inc.: Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering | CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,960 | -3,05 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| COGENT BIOSCIENCES | 36,630 | +2,35 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 323,50 | +1,46 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| JANUX THERAPEUTICS | 14,340 | -0,21 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| KINIKSA PHARMACEUTICALS | 55,23 | +2,70 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| CG ONCOLOGY | 66,21 | -0,79 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 1,960 | +10,73 % | Morning Market Movers: Sagimet Biosciences, Compass Therapeutics, Oruka Therapeutics, Veradermics See Big Swings | SAN DIEGO (dpa-AFX) - At 8:00 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 42,110 | +1,59 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| ZENAS BIOPHARMA | 19,360 | +0,21 % | Zenas BioPharma rises as CEO continues insider purchases | ||
| MINERALYS THERAPEUTICS | 29,300 | +9,94 % | Mineralys Therapeutics: TD Cowen startet Coverage mit Kaufempfehlung und sieht Blockbuster-Potenzial | ||
| ANNEXON | 5,750 | -2,04 % | Annexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones | ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with... ► Artikel lesen |
SHANGHAI HENLIUS BIOTECH INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,82 % bei einem Aktienkurs von 8,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HENLIUS BIOTECH INC finden Sie auf Wallstreet Online.